Chronic kidney disease

40 trials 14 recruiting MedDRA PT
40 Registered trials
14 Recruiting
19 Unique sponsors
19 Unique IMPs
24 Commercial trials
Drug classes (ATC)
— ATC code not specified 27
A Gastroenterology (ATC A) 9
C Cardiology (ATC C) 5
V Various (ATC V) 1
N Neurology/Psychiatry (ATC N) 1
Mechanism of action (INN-stem analysis)
Unknown / small molecule 15 substances
SGLT2 inhibitor 2 substances
Heparin / LMWH 1 substance
GLP-1 receptor agonist 1 substance
Phase III: 11 Phase II: 11 Phase IV: 7 Phase I: 1 Phase I (Other): 7 Other: 3

Filter these 40 trials by country, sponsor, date range and more.

Open in Search → Gap analysis →
Show: 40 trials

Phase III

11 trials
  • AstraZeneca AB Commercial
    DAPAGLIFLOZIN, ZIBOTENTAN
    2023-504124-26-00 12 countries 2024 n=328
    Ended
  • AstraZeneca AB Commercial
    BAXDROSTAT; DAPAGLIFLOZIN
    2023-506457-38-00 15 countries 2024 n=675
    Ended
  • AstraZeneca AB Commercial
    BAXDROSTAT; DAPAGLIFLOZIN
    2023-506460-14-00 15 countries 2025 n=1,134
    Recruiting
  • Bayer AG Commercial
    FINERENONE
    2022-503024-27-00 4 countries 2024 n=105
    Ended
  • Bayer AG Commercial
    FINERENONE
    2023-504884-17-00 17 countries 2022 n=245
    Ended
  • Bayer AG Commercial
    FINERENONE
    2023-504885-50-00 17 countries 2022 n=69
    Recruiting
  • Bayer AG Commercial
    FINERENONE
    2023-506897-11-00 9 countries 2021 n=391
    Ended
  • Centre Hospitalier Regional Universitaire De Tours Academic
    IMP not specified
    2022-501494-39-00 1 country 2023 n=720
    Recruiting
  • Centre Hospitalier Universitaire De Nantes Academic
    EMPAGLIFLOZIN
    2025-522119-41-00 1 country n=34
    Pending
  • The George Institute For Global Health Academic
    FINERENONE
    2024-511325-67-00 1 country n=300
    Not authorised
  • The George Institute For Global Health Academic
    FINERENONE
    2024-520253-21-00 2 countries 2026 n=250
    Recruiting

Phase II

11 trials
  • AstraZeneca AB Commercial
    BALCINRENONE, DAPAGLIFLOZIN; DAPAGLIFLOZIN
    2023-509709-63-00 5 countries 2024 n=85
    Ended
  • AstraZeneca AB Commercial
    BAXDROSTAT; DAPAGLIFLOZIN
    2025-522407-23-00 2 countries 2026 n=28
    Recruiting
  • Bayer AG Commercial
    BAY 3283142
    2023-505755-40-00 7 countries 2024 n=557
    Ended
  • Bayer AG Commercial
    BAY 3401016
    2024-516471-33-00 7 countries 2026 n=31
    Recruiting
  • Modus Therapeutics AB Commercial
    SEVUPARIN
    2024-513864-24-00 1 country 2024 n=60
    Recruiting
  • Novo Nordisk A/S Commercial
    CAGRILINTIDE; CAGRILINTIDE, SEMAGLUTIDE; SEMAGLUTIDE
    2023-505857-42-00 6 countries 2024 n=308
    Ended
  • Karolinska Institutet Academic
    IMP not specified
    2025-520550-11-00 1 country n=40
    Pending
  • Odense University Hospital Academic
    AMILORIDE HYDROCHLORIDE DIHYDRATE
    2022-500692-31-00 1 country 2024 n=40
    Recruiting
  • Odense University Hospital Academic
    IMP not specified
    2023-508516-34-00 1 country 2024 n=40
    Ended
  • Universitaetsklinikum Heidelberg AöR Academic
    SP16-3M
    2025-522491-89-00 1 country n=120
    Pending
  • Universitair Medisch Centrum Groningen Academic
    BI 690517; EMPAGLIFLOZIN; IOHEXOL; SPIRONOLACTONE
    2025-523743-35-00 1 country 2026 n=100
    Recruiting

Phase IV

7 trials
  • Aarhus University Hospital Academic
    FINERENONE
    2023-504446-58-00 1 country 2024 n=80
    Recruiting
  • Centre Hospitalier Universitaire De Nantes Academic
    DAPAGLIFLOZIN
    2023-506295-26-00 1 country 2023 n=70
    Ended
  • Narodowy Instytut Onkologii Im. Marii Sklodowskiej-Curie Panstwowy Instytut Badawczy Academic
    CYTISINICLINE; NICOTINE
    2023-509235-39-00 1 country 2025 n=292
    Recruiting
  • Region Midtjylland Academic
    FINERENONE; SEMAGLUTIDE
    2025-522503-18-00 1 country 2025 n=160
    Recruiting
  • Steno Diabetes Center Copenhagen Academic
    IMP not specified
    2023-507449-27-00 5 countries n=115
    Not authorised
  • Steno Diabetes Center Copenhagen Academic
    FINERENONE
    2023-507449-27-01 5 countries 2025 n=115
    Recruiting
  • Universitaetsklinikum Tuebingen AöR Academic
    DAPAGLIFLOZIN
    2024-512179-11-00 1 country 2023 n=182
    Recruiting

Phase I

1 trial
  • Novartis Pharma AG Commercial
    IMP not specified
    2025-520978-18-00 2 countries n=44
    Pending

Phase I (Other)

7 trials

Other

3 trials
  • Adamed Pharma S.A. Commercial
    IMP not specified
    2025-522975-27-00 1 country 2025 n=44
    Ended
  • Adamed Pharma S.A. Commercial
    IMP not specified
    2025-522976-10-00 1 country 2025 n=44
    Ended
  • Laboratorios Cinfa S.A. Commercial
    IMP not specified
    2025-522234-31-00 1 country 2025 n=32
    Ended
Sponsor activity
SponsorTypeTrialsPhasesRecruiting
Bayer AG Commercial 12 Phase I (Other), Phase II, Phase III 2
AstraZeneca AB Commercial 6 Phase I (Other), Phase II, Phase III 2
Adamed Pharma S.A. Commercial 2 Other 0
Odense University Hospital Academic 2 Phase II 1
Centre Hospitalier Universitaire De Nantes Academic 2 Phase III, Phase IV 0
The George Institute For Global Health Academic 2 Phase III 1
Steno Diabetes Center Copenhagen Academic 2 Phase IV 1
Novartis Pharma AG Commercial 1 Phase I 0
Laboratorios Cinfa S.A. Commercial 1 Other 0
Modus Therapeutics AB Commercial 1 Phase II 1
Novo Nordisk A/S Commercial 1 Phase II 0
Karolinska Institutet Academic 1 Phase II 0
Universitaetsklinikum Heidelberg AöR Academic 1 Phase II 0
Universitair Medisch Centrum Groningen Academic 1 Phase II 1
Centre Hospitalier Regional Universitaire De Tours Academic 1 Phase III 1
Aarhus University Hospital Academic 1 Phase IV 1
Narodowy Instytut Onkologii Im. Marii Sklodowskiej-Curie Panstwowy Instytut Badawczy Academic 1 Phase IV 1
Region Midtjylland Academic 1 Phase IV 1
Universitaetsklinikum Tuebingen AöR Academic 1 Phase IV 1
New trials by year
2021
1
2022
2
2023
3
2024
13
2025
8
2026
4
← All indication landscapes